🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Elanco shares target cut by Piper Sandler amid new product label impact

EditorEmilio Ghigini
Published 07/01/2024, 07:41 AM
ELAN
-

On Monday, Elanco Animal Health (NYSE:ELAN) shares saw its price target lowered by Piper Sandler from $19.00 to $16.00, while the firm kept a Neutral stance on the stock. The adjustment comes after Piper Sandler conducted interviews with three veterinary professionals to gauge the potential impact of Elanco's new product label on prescribing habits.

The consensus from the interviews suggests that the new label may lead to a roughly 20% discount on the product and a slower adoption rate among veterinarians, who may require time to build confidence in the product.

Piper Sandler anticipates that at the product's peak, there might be a modest 5-10% decline in unit volume. However, due to the lower price, the impact on margins could be more significant than initially expected.

The firm projects a total impact of 25-35% on peak sales for Elanco, coupled with a more gradual increase in sales. In response to these insights, Piper Sandler has revised its model, leading to the updated price target of $16. This reflects the anticipated challenges in the product's market performance and the potential financial implications for Elanco.

The maintained Neutral rating indicates that Piper Sandler does not see significant positive or negative catalysts that could drive Elanco's stock performance markedly above or below its current level in the near term. The firm's revised price target and outlook are based on the expected impact of the new product label on Elanco's sales trajectory and profit margins.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.